Procognia's U-c Fingerprint Technology to be Used for Rapid Glycoanalysis at the Centre for Bioanalytical Sciences.MAIDENHEAD Maidenhead, city (1991 pop. 59,809), Windsor and Maidenhead, S central England, on the Thames River. It is a residential town with brewing and milling industries as well as a resort. The 13th-century stone bridge was rebuilt in the 1770s. , United Kingdom -- Procognia Ltd today announced that Procognia, Bristol-Myers Squibb Bristol-Myers Squibb (NYSE: BMY), colloquially referred to as BMS, is a pharmaceutical corporation, formed by a 1989 merger between pharmaceutical companies Bristol-Myers Company, founded in 1887 by William McLaren Bristol and John Ripley Myers in Clinton, NY (both were Company, its Irish subsidiary Swords Laboratories, Dublin City University Dublin City University (DCU) (Irish: Ollscoil Chathair Bhaile Átha Cliath) is a university situated between Glasnevin and Whitehall on the Northside of Dublin in Ireland. , and National University of Ireland, Galway History The college opened for teaching in 1849 as Queen's College, Galway with 37 professors and 91 students and a year later became a part of the Queen's University of Ireland. (NUIG NUIG National University of Ireland, Galway ) signed an agreement to use Procognia's U-c fingerprint technology for rapid glycoanalysis at the Centre for Bioanalytical Sciences. Established in 2005, the Centre is being funded by IDA Ireland and Bristol-Myers Squibb to perform research and development related to new sciences and techniques needed to understand the dynamics of bioreactions. Procognia's U-c fingerprint technology will be used for the rapid assessment of product structure and comparability via analysis of the glycosylation of intact glycoprotein glycoprotein (glī'kōprō`tēn), organic compound composed of both a protein and a carbohydrate joined together in covalent chemical linkage. samples directly in culture medium. Bristol-Myers Squibb is a leader in the field of biotherapeutic discovery and production and NUIG is at the forefront of using novel glycoanalytical technologies to characterise biotherapeutics. Procognia's U-c fingerprint technology provides a quantitative analysis Quantitative Analysis A security analysis that uses financial information derived from company annual reports and income statements to evaluate an investment decision. Notes: of the glycans in a protein sample without protein purification or cleavage. Protein samples can be analysed in under four hours with minimal 'hands-on' time. As current tools for analysing glycosylation are not amenable to real-time analysis and monitoring, Procognia anticipates that the speed and ease of use of its technology will enable rapid development of biotherapeutics. NUIG aim to use Procognia's U-c fingerprint technology to identify and retain the desired glycosylation patterns of biological products as they undergo process optimisation, scale up for manufacturing and clinical development. Ron Long, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Procognia said "We are delighted that Bristol-Myers Squibb Company and National University of Ireland, Galway have recognised that understanding glycosylation is important in the development of effective new biotherapeutics and that Procognia's U-c fingerprint technology is expected to obtain the required data quickly and efficiently." Financial terms of the agreement were not disclosed. About Procognia Procognia has developed integrated, rapid glycoanalysis technologies to increase the probability of success of biopharmaceutical products. Procognia technology can provide more data in hours than combinations of conventional methods can provide in considerably more time. The company has its corporate headquarters in Maidenhead, United Kingdom. R&D takes place in Ashdod, Israel and Maidenhead, United Kingdom. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion